Published by Benjamin Chiou on 6th October 2026
(Sharecast News) - Shares in Danish biotech group Genmab jumped to a three-year high on Tuesday after a late-stage trial of its lymphoma treatment developed with AbbVie delivered better outcomes than the current standard therapy.
URL: http://www.digitallook.com/dl/news/story/36260535/...